May 3, 2005
By 1996, when improved treatment options became available and HIV-positive people were living longer, interest in long-term nonprogressors had decreased, according to the Times. However, when it "became apparent that a vaccine was still sorely needed," the interest "re-emerged," according to Dr. Mike McCune, senior investigator at the Gladstone Institute of Virology and Immunology, the Times reports. Some vaccine researchers who also study nonprogressors are focusing on the early stages of HIV to determine what types of immune system responses are useful against the virus and when they are most effective. "The main thing long-term nonprogressors teach us, and it keeps coming back again and again and again, is that it's not just the virus, it's the host," McCune said (Pogash, New York Times, 5/3).
Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2004 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.